Lentigen s Boro Dropulic on Commercializing Lentiviral Vectors for RNAi

Nov 11, 2005

Premium

Boro Dropulic
Founder, CEO
Lentigen

Name: Boro Dropulic

Position: Founder, CEO, Lentigen

Background: Founder, CSO, Virxsys 1999 2004

Education: MBA, Johns Hopkins University 2004

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Search Decisions

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

The Mouse of the Situation

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

Pain Targeted

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

Science Presents Malaria Cell Atlas, More

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.

Featured White Papers

Automated Genomic DNA Extraction from Large Volume Whole Blood

RNAGEM - mRNA Profiles as Close to Biological Reality as Possible

Application Note: How to Pipette PCR Master Mix for Increased Accuracy in qPCR Results

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Aug

28

Featured Webinar

Beyond Cas9: CRISPR Gene Editing with Alternative Nucleases

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu